ARS Pharmaceuticals, Inc. 8K

ARS Pharmaceuticals reported Q2 2026 results, realigned its neffy commercial strategy toward targeted prescribers with substantial SG&A cuts and a path to cash flow breakeven by end‑2027, appointed a new Chief Commercial Officer, and updated guidance and timelines for its CSU Phase 2b program.

On August 13, 2026, ARS Pharmaceuticals, Inc. reported its second quarter 2026 financial results and outlined updated strategic priorities centered on a more targeted commercial strategy for its epinephrine nasal spray product neffy, including shifting spending from broad consumer marketing to high‑value prescriber engagement, materially reducing SG&A expenses for the second half of 2026, and targeting cash flow breakeven by the end of 2027. The company announced U.S. neffy net product revenue of $26.2 million for Q2 2026, representing 5% total U.S. epinephrine market share and 8% share within field‑targeted accounts, alongside a Q2 net loss of $62.3 million and a cash balance of $143.8 million as of June 30, 2026. ARS also strengthened its commercial leadership by appointing Meg Smith as Chief Commercial Officer effective August 17, 2026, completed expansion of its field sales force, and provided updated operating expense guidance for 2H 2026 in the range of $114–$126 million (including stock‑based compensation), reflecting over a 40% reduction in cash‑based SG&A from 1H 2026. In addition, the company highlighted progress in its chronic spontaneous urticaria (CSU) program (ARS‑2), with a Phase 2b trial underway and interim data expected in Q1 2027, positioning the intranasal epinephrine platform as a potential additional growth driver leveraging existing commercial infrastructure.

Filing Facts

CIK

1671858

Ticker

SPRY

Form

8K

Source Type

fda

Accession

0001193125-26-349127

Alert Tier

6